9th Commercialising Continuous Processing Summit 2025
The pivotal shift in biopharma priorities is steering towards enhancing sustainability measures for drug development. Continuous processing keeps the industry grounded in reaching propelled ESG goals whilst keeping capital spend to a minimum. With the previous release of the ICH Q13 broadening the scope of support for continuous manufacturing as a greener alternative, continuous processing is unstoppable in its efforts to drive formulation efficiency and supply chain resilience across all modalities.
In collaboration with AstraZeneca, Pfizer, Sanofi, and Ultragenyx, the 9th Commercializing Continuous Processing Summit returns to you with a new strategic focus and novel case-studies spanning small molecule, biologics and emerging modalities to secure internal support for your continuous shift, and edge towards first-class, quality therapeutics for patients.
What will you learn at the 9th CCP Summit?
- Uncover process modeling advancements to aid small molecule tech transfer and minimize troubleshooting time
- Explore revolutionary ADC and peptide production case-studies to transform traditional biologics development
- Assess modality agnostic learnings across PAT and CDMO management to promote end-to-end processing success
- Identify digital twin applications for new levels of efficiency during continuous processing
- Learn from pharma-led continuous processing projects across small molecule, biologics, cell and gene therapy to optimize yields, and enhance green chemistry
Whether you are specialized in small molecule, biologics, or cell and gene therapy, the 9th CCP Summit caters to all. Join 60+ of your peers across process development, CMC, and analytical development to revolutionize your development pipeline.
Find out more here: https://ter.li/ua5eov
